COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G3AT
|
|||
| Drug Name |
GC813
|
|||
| Synonyms |
GC813 compound
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [1] |
| GC813 inhibits MERS-CoV 3CLpro protease illuminated by determining X-ray crystal structure of the MERS-CoV 3CLpro and inhibitor GC813:GC813 complex. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Structure-guided Design of Potent and Permeable Inhibitors of MERS Coronavirus 3CL Protease That Utilize a Piperidine Moiety as a Novel Design Element Eur J Med Chem. 2018 Apr 25;150:334-346. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.